Efficacy in intra-oesophageal acid suppression may decrease after 2-year continuous treatment with proton pump inhibitors

Digestive and Liver Disease

Volumn 39, Issue 5, 2007, Pages 415-421

  Frazzoni, M ^a   Manno, M ^a   De Micheli, E ^a   Savarino, V ^b  

^a Nuovo Ospedale S Agostino   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Gastro oesophageal reflux disease; Proton pump inhibitors

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; ESOPHAGEAL PH MONITORING; ESOPHAGITIS; ESOPHAGOSCOPY; ESOPHAGUS MANOMETRY; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HUMAN; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT DURATION;

ADULT; AGED; BARRETT ESOPHAGUS; DRUG TOLERANCE; ENZYME INHIBITORS; ESOPHAGITIS, PEPTIC; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMPS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33947721974     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.01.023     Document Type: Article

References (46)

1. DeVault K.R., and Castell D.O. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100 (2005) 190-200
2. Lundell L.R., Dent J., Bennett J.R., Blum A.L., Armstrong D., Galmiche J.P., et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 45 (1999) 172-180
3. Frazzoni M., De Micheli E., and Savarino V. Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease. Aliment Pharmacol Ther 18 (2003) 1091-1098
4. Dent J., Brun J., Fendrick A.M., Fennerty M.B., Janssens J., Kahrilas P.J., et al. An evidence-based appraisal of reflux disease management-the Genval Workshop Report. Gut 44 suppl. 2 (1999) S1-S16
5. Dent J., and Talley N.J. Overview: initial and long-term management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 17 Suppl. 1 (2003) 53-57
6. Jankowski J., and Sharma P. Review article: approaches to Barrett's oesophagus treatment-the role of proton pump inhibitors and other interventions. Aliment Pharmacol Ther 19 Suppl 1 (2004) 54-59
7. Klinkenberg-Knol E.C., Nelis F., Dent J., Snel P., Mitchell B., Prichard P., et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 118 (2000) 661-669
8. Lundell L., Miettinen P., Myrvold H.E., Pedersen S.A., Liedman B., Hatlebakk J.G., et al. Continued (5-year) follow-up of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 192 (2001) 172-179
9. Geboes K., Dekker W., Mulder C.J.J., and Nusteling K. Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther 15 (2001) 1819-1826
10. Thjodleifsson B., Rindi G., Fiocca R., Humphries T.J., Morocutti A., Miller N., et al. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol Ther 17 (2003) 343-351
11. Caos A., Breiter J., Perdomo C., and Barth J. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther 22 (2005) 193-202
12. Tefera S., Hatlebakk J.G., and Berstad A. Stability of gastric secretory inhibition during 6-month treatment with omeprazole in patients with gastroesophageal reflux disease. Am J Gastroenterol 96 (2001) 969-974
13. Armstrong D., Bennett J.R., Blum A.L., Dent J., De Dombal F.T., Galmiche J.P., et al. The endoscopic assessment of esophagitis. A progress report on observer agreement. Gastroenterology 111 (1996) 85-92
14. Sampliner R.E., and The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 97 (2002) 1888-1895
15. Frazzoni M., Lonardo A., Grisendi A., Della Casa G., Pulvirenti M., Ferrari A.M., et al. Are routine duodenal and antral biopsies useful in the management of "functional" dyspepsia? A diagnostic and therapeutic study. J Clin Gastroenterol 17 (1993) 101-108
16. Passaretti S., Zaninotto G., Di Martino N., Leo P., Costantini M., and Baldi F. Standards for oesophageal manometry. A position statement from the Gruppo Italiano di Studio Motilità Apparato Digerente (GISMAD). Dig Liver Dis 32 (2000) 46-55
17. Richter J.E., Bradley L.A., DeMeester T.R., and Wu W.C. Normal 24-hour ambulatory esophageal pH values. Influence of study center, pH electrode, age, and gender. Dig Dis Sci 37 (1992) 849-856
18. Ouatu-Lascar R., Fitzgerald R.C., and Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 117 (1999) 327-335
19. Dent J. Definition of reflux disease and its separation from dyspepsia. Gut 50 Suppl. IV (2002) iv17-iv20
20. 2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 122 (2002) 625-632
21. Frazzoni M., De Micheli E., Zentilin P., and Savarino V. Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther 20 (2004) 81-88
22. Frazzoni M., De Micheli E., Grisendi A., and Savarino V. Lansoprazole vs. omeprazole for gastrooesophageal reflux disease: a pH-metric comparison. Aliment Pharmacol Ther 16 (2002) 35-40
23. Frazzoni M., De Micheli E., Grisendi A., and Savarino V. Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. Aliment Pharmacol Ther 17 (2003) 235-241
24. Frazzoni M., Manno M., De Micheli E., and Savarino V. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole vs. lansoprazole. Dig Liver Dis 38 (2006) 85-90
25. Jamieson J.R., Stein H.J., DeMeester T.R., Bonavina L., Schwizer W., Hinder R.A., et al. Ambulatory 24-h esophageal pH monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility. Am J Gastroenterol 87 (1992) 1102-1111
26. Kahrilas P.J., and Quigley E.M.M. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 110 (1996) 1982-1986
27. Singh S., and Richter J.E. Effects of a pH electrode across the lower esophageal sphincter. Dig Dis Sci 37 (1992) 667-672
28. Buckles D.C., Sarosiek I., McMillin C., and McCallum R.W. Delayed gastric emptying in gastroesophageal reflux disease: reassessment with new methods and symptomatic correlations. Am J Med Sci 327 (2004) 1-4
29. Armstrong D. Review article: gastric pH-the most relevant predictor of benefit in reflux disease?. Aliment Pharmacol Ther 20 Suppl. 5 (2004) 19-26
30. Egan L.J., Myhre G.M., Mays D.C., Dierkhising R.A., Kammer P.P., and Murray J.A. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment Pharmacol Ther 17 (2003) 1521-1528
31. Milkes D., Gerson L.B., and Triadafilopoulos G. Complete elimination pf reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol 98 (2004) 991-996
32. Spechler S.J., Sharma P., Traxler B., Levine D., and Falk J.W. Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomised, double-blind, crossover trial. Am J Gastroenterol 101 (2006) 1964-1971
33. Pace F., Bollani S., Molteni P., and Bianchi Porro G. Natural history of gastro-oesophageal reflux disease without oesophagitis (NERD)-a reappraisal 10 years on. Dig Liver Dis 36 (2004) 111-115
34. Ruigomez A., Garcia Rodriguez L.A., Wallander M.A., Johansson S., Graffner H., and Dent J. Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther 20 (2004) 751-760
35. Fullard M., Kang J.Y., Neild P., Poullis A., and Maxwell J.D. Systematic review: does gastro-oesophageal reflux disease progress?. Aliment Pharmacol Ther 24 (2006) 33-45
36. Labenz J., Nocon M., Lind T., Leodolter A., Jaspersen D., Meyer-Sabellek W., et al. Prospective follow-up data from the ProGERD study suggests that GERD is not a categorial disease. Am J Gastroenterol 101 (2006) 2457-2462
37. Singh P., Taylor R.H., and Colin-Jones D.G. Simultaneous two level oesophageal pH monitoring in healthy controls and patients with oesophagitis: comparison between two positions. Gut 35 (1994) 304-308
38. Meshkinpour H. Esophageal aperistalsis and gastroesophageal reflux disorder: return of peristalsis after H2-blocker therapy. Am J Gastroenterol 90 (1995) 910-914
39. Dent J. Management of reflux disease. Gut 50 Suppl. IV (2002) iv67-iv71
40. Pehlivanov N.D., Olyaee M., Sarosiek I., and McCallum R.W. Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. Aliment Pharmacol Ther 18 (2003) 1-8
41. Wu J.C.Y., Chan F.K.L., Ching J.W.L., Leung W.-K., Hui Y., Leong R., et al. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut 53 (2004) 174-179
42. Weston A.P., Badr A.S., Topalovski M., Cherian R., Dixon A., and Hassanein R.S. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GORD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma. Am J Gastroenterol 95 (2000) 387-394
43. Wu J.C.Y., Sung J.J.Y., Chan F.K.L., Ching J.Y.L., Ng A.C.W., Go M.Y.Y., et al. Helicobacter pylori infection is associated with milder gastro-oesophageal reflux disease. Aliment Pharmacol Ther 14 (2000) 427-432
44. Katzka D.A., and Castell D.O. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 89 (1994) 989-991
45. Ouatu-Lascar R., and Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 93 (1998) 711-716
46. Holloway R.H., Dent J., Narielvala F., and Mackinnon A.M. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 38 (1996) 649-654